The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
Open accessAbstract
PURPOSE: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. PATIENTS AND METHODS: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. RESULTS: Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse-free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low beta 2-microglobulin level (< 4 g/L) also tended to have a favorable prognostic impact. The most important post-transplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. CONCLUSION: Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R., Thomas, E. D., & The Seattle Marrow Transplant Team (1981) · New England Journal of Medicine · doi:10.1056/nejm198106183042507 · Cited by 1,081
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens
Alexanian, R. (1969) · JAMA · doi:10.1001/jama.208.9.1680 · Cited by 499
Allogeneic Bone Marrow Transplantation in Multiple Myeloma
Gahrton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M., Gratwohl, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251802 · Cited by 378
Self-citationGreipp, P., Lust, J., O'Fallon, W., Katzmann, J., Witzig, T., & Kyle, R. (1993) · Blood · doi:10.1182/blood.v81.12.3382.3382 · Cited by 312
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
Bataille, R., Boccadoro, M., Klein, B., Durie, B., & Pileri, A. (1992) · Blood · doi:10.1182/blood.v80.3.733.733 · Cited by 294
Durie, B., Stock-Novack, D., Salmon, S., Finley, P., Beckord, J., Crowley, J., & Coltman, C. (1990) · Blood · doi:10.1182/blood.v75.4.823.823 · Cited by 188
Intensive combined therapy for previously untreated aggressive myeloma
Attal, M., Huguet, F., Schlaifer, D., Payen, C., Laroche, M., Fournié, B., Mazieres, B., Pris, J., & Laurent, G. (1992) · Blood · doi:10.1182/blood.v79.5.1130.1130 · Cited by 146
Gratwohl, A. A., Hermans, J., Niederwieser, D. W., Frassoni, F., Arcese, W., Gahrton, G., Bandini, G., Carreras, E., Vernant, J., & Bosi, A. (1993) · PubMed · Cited by 140
Self-citationÖsterborg, A., Björkholm, M., Björeman, M., Brenning, G., Carlson, K. E., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammar, H., & Hast, R. (1993) · Blood · doi:10.1182/blood.v81.6.1428.1428 · Cited by 104
Self-citation
Cited by
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citationBarlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Spitzer, T. R., Delmonico, F., Tolkoff-Rubin, N., McAfee, S., Sackstein, R., Saidman, S., Colby, C., Sykes, M., Sachs, D. H., & Cosimi, A. B. (1999) · Transplantation · doi:10.1097/00007890-199908270-00006 · Cited by 419
Metadata
- Authors
- Gahrton, G., Tura, S., Ljungman, P., Bladé, J., Brandt, L., Cavo, M., Façon, T., Gratwohl, A., Hagenbeek, A., & Jacobs, P.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-06
- Volume
- 13
- Issue
- 6
- Pages
- 1312-1322
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1914208484
- Cited by
- 285
- References
- 12
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. https://app.cochat.ai/papers/10.1200/jco.1995.13.6.1312
- The paper
- Gahrton, G., Tura, S., Ljungman, P., Bladé, J., Brandt, L., Cavo, M., Façon, T., Gratwohl, A., Hagenbeek, A., & Jacobs, P. (1995). Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.6.1312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.